

DESCRIPTION



| | |
|---------------------------|---|
| Species Reactivity | Human |
| Specificity | Detects human PD-1 in direct ELISAs. |
| Source | Monoclonal Mouse IgG ₁ Clone # 1026519 |
| Purification | Protein A or G purified from cell culture supernatant |
| Immunogen | Synthetic peptide containing human PD-1 |
| Formulation | Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. See Certificate of Analysis for details. *Small pack size (-SP) is supplied either lyophilized or as a 0.2 μm filtered solution in PBS. |

APPLICATIONS

Please Note: Optimal dilutions should be determined by each laboratory for each application. General Protocols are available in the Technical Information section on our website.

| | Recommended Concentration | Sample |
|-----------------------|--|---|
| Western Blot | 2 μg/mL | NS0 mouse myeloma cell line transfected with human PD-1 |
| Flow Cytometry | 0.25 μg/10 ⁶ cells | HEK293 Human Cell Line transfected with Human PD-1 and eGFP |
| CyTOF-ready | Ready to be labeled using established conjugation methods. No BSA or other carrier proteins that could interfere with conjugation. | |

DATA

| | |
|--|---|
| <p>Western Blot</p>  <p>Detection of Human PD-1 by Western Blot. Western blot shows lysates of NS0 mouse myeloma cell line mock transfected or transfected with human PD-1. PVDF membrane was probed with 2 μg/mL of Mouse Anti-Human PD-1 Monoclonal Antibody (Catalog # MAB10866) followed by HRP-conjugated Anti-Mouse IgG Secondary Antibody (Catalog # HAF018). A specific band was detected for PD-1 at approximately 75 kDa (as indicated). GAPDH (Catalog # 2275-PC-100) is shown as a loading control. This experiment was conducted under reducing conditions and using Western Blot Buffer Group 1.</p> | <p>Flow Cytometry</p>  <p>Detection of PD-1 in HEK293 Human Cell Line transfected with Human PD-1 and eGFP by Flow Cytometry HEK293 human embryonic kidney cell line transfected with either (A) human PD-1 or (B) irrelevant protein, and eGFP, was stained with Mouse anti-human PD-1 monoclonal antibody (Catalog # MAB10866) followed by Allophycocyanin-conjugated anti-Mouse IgG Secondary Antibody (Catalog # F0101B). Quadrant markers were set based on control antibody staining (Catalog # MAB002, data not shown). Staining was performed using our Staining Membrane-Associated Proteins protocol.</p> |
|--|---|

PREPARATION AND STORAGE

| | |
|--------------------------------|---|
| Reconstitution | Reconstitute at 0.5 mg/mL in sterile PBS. |
| Shipping | The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below. *Small pack size (-SP) is shipped with polar packs. Upon receipt, store it immediately at -20 to -70 °C |
| Stability & Storage | <p>Use a manual defrost freezer and avoid repeated freeze-thaw cycles.</p> <ul style="list-style-type: none"> • 12 months from date of receipt, -20 to -70 °C as supplied. • 1 month, 2 to 8 °C under sterile conditions after reconstitution. • 6 months, -20 to -70 °C under sterile conditions after reconstitution. |

BACKGROUND

Programmed Death-1 receptor (PD-1), also known as CD279, is type I transmembrane protein belonging to the CD28 family of immune regulatory receptors (1). Other members of this family include CD28, CTLA-4, ICOS, and BTLA (2-5). Mature human PD-1 consists of a 148 amino acid (aa) extracellular region (ECD) with one immunoglobulin-like V-type domain, a 24 aa transmembrane domain, and a 95 aa cytoplasmic region. The human PD-1 ECD shares 65% aa sequence identity with the mouse PD-1 ECD. The cytoplasmic tail contains two tyrosine residues that form the immunoreceptor tyrosine-based inhibitory motif (ITIM) and immunoreceptor tyrosine-based switch motif (ITSM) that are important for mediating PD-1 signaling. PD-1 acts as a monomeric receptor and interacts in a 1:1 stoichiometric ratio with its ligands PD-L1 (B7-H1) and PD-L2 (B7-DC) (6, 7). PD-1 is expressed on activated T cells, B cells, monocytes, and dendritic cells while PD-L1 expression is constitutive on the same cells and also on nonhematopoietic cells such as lung endothelial cells and hepatocytes (8, 9). Ligand of PD-L1 with PD-1 induces co-inhibitory signals on T cells promoting their apoptosis, anergy, and functional exhaustion (10). Thus, the PD-1: PD-L1 interaction is a key regulator of the threshold of immune response and peripheral immune tolerance (11). Finally, blockade of the PD-1: PD-L1 interaction by either antibodies or genetic manipulation accelerates tumor eradication and shows potential for improving cancer immunotherapy (12, 13, 14).

References:

1. Ishida, Y. *et al.* (1992) *EMBO J.* **11**:3887.
2. Sharpe, A.H. and G. J. Freeman (2002) *Nat. Rev. Immunol.* **2**:116.
3. Coyle, A. and J. Gutierrez-Ramos (2001) *Nat. Immunol.* **2**:203.
4. Nishimura, H. and T. Honjo (2001) *Trends Immunol.* **22**:265.
5. Watanabe, N *et al.* (2003) *Nat. Immunol.* **4**:670.
6. Zhang, X. *et al.* (2004) *Immunity* **20**:337.
7. Lázár-Molnár, E. *et al.* (2008) *Proc. Natl. Acad. Sci. USA* **105**:10483.
8. Nishimura, H *et al.* (1996) *Int. Immunol.* **8**:773.
9. Keir, M.E. *et al.* (2008) *Annu. Rev. Immunol.* **26**:677.
10. Butte, M.J. *et al.* (2007) *Immunity* **27**:111.
11. Okazaki, T. *et al.* (2013) *Nat. Immunol.* **14**:1212.
12. Iwai, Y. *et al.* (2002) *Proc. Natl. Acad. Sci. USA* **99**: 12293.
13. Nogrady, B. (2014) *Nature* **513**:S10.
14. Swaika, A. *et al.* (2015) *Mol. Immunol.* **67**: 4